Form D · Biotechnology
Gloucester Pharmaceuticals Inc
Cambridge, MA · CIK 0001307826
Offering snapshot reported Aug 21, 2009 · SEC filing
- Reported sold
- $20.3M Offering amount: $28.9M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 14, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 21, 2009 | Initial | $20,324,914 | No comparison | 9 | SEC filing |
| Aug 12, 2009 | Initial | $500,000 | No comparison | 8 | SEC filing |
| Jul 17, 2009 | Initial | $500,000 | No comparison | 8 | SEC filing |
| Jun 10, 2009 | Initial | $1,500,000 | No comparison | 8 | SEC filing |
| May 6, 2009 | Initial | $1,700,000 | No comparison | Not reported | SEC filing |
| Apr 10, 2009 | Initial | $1,500,000 | No comparison | Not reported | SEC filing |
| Feb 19, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 1, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 6, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 15, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 10, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 1, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 27, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 22, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-70770
Total amount sold includes approximately $8.9 million worth of equity issued from converted bridge debt.
Source: Form D, filed Aug 21, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alan B. Colowick | Director, Executive |
| Thomas Dyrberg | Director |
| Seth Harrison | Director |
| Donald J. Hayden | Director, Executive |
| Jay Moorin | Director |
| Jean C. Nichols | Executive |
| David Schnell | Director |
| Martin Vogelbaum | Director |
| Nicholas Vrolijk | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Broadway 14 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142